InvestorsHub Logo
Followers 17
Posts 1798
Boards Moderated 0
Alias Born 10/11/2007

Re: rusbrn post# 32443

Friday, 02/26/2010 2:45:40 PM

Friday, February 26, 2010 2:45:40 PM

Post# of 48484
Apparently APN01 is potentially a far better drug than CX-717. The argument that this indication is too difficult to create study now holds little water. Either poor marketing by Cor management or a poor molecule. You decide. With a potential $330 million payday, future trial design does not appear an issue, but clearly for Cor it's another phantom excuse. Not to mention the so called tightening of BP's partnering belt.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News